Table 1.

Patient demographics and baseline characteristics.

CharacteristicPlacebo, n = 223Treatment Group Milnacipran 100 mg/day, n = 224Milnacipran 200 mg/day, n = 441
Age, mean (SD), years49.4 (10.1)49.9 (10.6)49.2 (11.0)
Sex, n (%)
  Female213 (95.5)213 (95.1)423 (95.9)
  Male10 (4.5)11 (4.9)18 (4.1)
Race, n (%)
  White211 (94.6)208 (92.9)412 (93.4)
  American-Indian/Alaska Native1 (0.4)2 (0.9)2 (0.5)
  Asian1 (0.4)1 (0.4)3 (0.7)
  Black7 (3.1)12 (5.4)17 (3.9)
  Other3 (1.3)1 (0.4)7 (1.6)
Weight, mean (SD), lb181.9 (40.7)180.6 (41.4)181.3 (44.3)
BMI, mean (SD)30.4 (6.5)30.4 (6.6)30.6 (7.4)
FM duration, mean (SD), yrs6.0 (5.9)5.6 (5.3)5.5 (5.1)
PED daily morning recall pain score (SD), range 0–10068.3 (11.9)68.3 (11.5)69.4 (11.9)
Paper VAS 24-h recall pain score (SD), range 0–10074.3 (15.1)73.0 (16.0)73.9 (16.3)
FIQ total score (SD), range 0–10064.7 (13.4)65.1 (13.7)64.3 (14.4)
SF-36 PCS score (SD)31.4 (7.8)30.8 (7.6)31.4 (8.0)
SF-36 MCS score (SD)42.1 (12.1)42.4 (11.4)41.5 (11.7)
BDI score (SD), range 0–6314.1 (9.5)13.2 (7.7)14.4 (8.6)
MFI total score (SD), range 20–10067.0 (13.0)67.5 (13.1)67.8 (13.3)
MASQ total score (SD), range 38–19088.5 (19.2)88.4 (19.7)89.4 (18.1)
  • BDI: Beck Depression Inventory; BMI: body mass index; FIQ: Fibromyalgia Impact Questionnaire; MCS: Mental Component Summary; MFI: Multidimensional Fatigue Inventory; MASQ: Multiple Ability Self-Report Questionnaire; PED: patient experience diary; PCS: Physical Component Summary; VAS: visual analog scale.